Effectiveness of 2009 pandemic influenza A(H1N1) vaccines: A systematic review and meta-analysis

Vaccine

Volumn 35, Issue 16, 2017, Pages 1996-2006

  Lansbury, Louise E ^a   Smith, Sherie ^a   Beyer, Walter ^b   Karamehic, Emina ^c   Pasic Juhas, Eva ^c   Sikira, Hana ^c   Mateus, Ana ^d   Oshitani, Hitoshi ^e   Zhao, Hongxin ^f   Beck, Charles R ^f,g   Nguyen Van Tam, Jonathan S ^a,f  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF SARAJEVO   (Bosnia and Herzegovina)

^d ROYAL VETERINARY COLLEGE   (United Kingdom)

^e TOHOKU UNIVERSITY   (Japan)

^f PUBLIC HEALTH ENGLAND   (United Kingdom)

^g UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

A(H1N1)pdm09; Effectiveness; Influenza; Meta analysis; Systematic review; Vaccination

Indexed keywords

INFLUENZA VACCINE; IMMUNOLOGICAL ADJUVANT;

2009 H1N1 INFLUENZA; ADULT; CHILD; CLINICAL EFFECTIVENESS; DRUG EFFICACY; GROUPS BY AGE; HOSPITALIZATION; HUMAN; INFLUENZA VACCINATION; META ANALYSIS; PANDEMIC INFLUENZA; PRIORITY JOURNAL; RANDOMIZATION; REVIEW; SELECTION BIAS; SYSTEMATIC REVIEW; IMMUNOLOGY; INFLUENZA; INFLUENZA A VIRUS (H1N1); TREATMENT OUTCOME; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; TREATMENT OUTCOME;

EID: 85016279912     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.02.059     Document Type: Review

References (69)

1. [1] Yin, J.K., Chow, M.Y., Khandaker, G., King, C., Richmond, P., Heron, L., et al. Impacts on influenza A(H1N1)pdm09 infection from cross-protection of seasonal trivalent influenza vaccines and A(H1N1)pdm09 vaccines: systematic review and meta-analyses. Vaccine 30 (2012), 3209–3222.
2. [2] Osterholm, M.T., Kelley, N.S., Sommer, A., Belongia, E.A., Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 12 (2012), 36–44.
3. [3] Yin, J.K., Khandaker, G., Rashid, H., Heron, L., Ridda, I., Booy, R., Immunogenicity and safety of pandemic influenza A (H1N1) 2009 vaccine: systematic review and meta-analysis. Influenza Other Respir Viruses 5 (2011), 299–305.
4. [4] Beck C, Nguyen-Van-Tam J, Lansbury L, Smith S. Efficacy and effectiveness of 2009 pandemic influenza A(H1N1) vaccines: a systematic review and meta-analysis. PROSPERO 2014:CRD42014014384.
5. [5] European Centre for Disease Prevention and Control. Narcolepsy in association with pandemic influenza vaccination (A multi-country European epidemiological investigation). Stockholm: ECDC; September 2012.
6. [6] Nohynek, H., Jokinen, J., Partinen, M., Vaarala, O., Kirjavainen, T., Sundman, J., et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS ONE, 7, 2012, e33536.
7. [7] Medical Products Agency Sweden. Occurrence of narcolepsy with cataplexy among children and adolescents in relation to the H1N1 pandemic and Pandemrix vaccinations. Results of a case inventory study by the MPA in Sweden during 2009–2010. Available from: < http://www.lakemedelsverket.se/upload/nyheter/2011/Fallinventeringsrapport_pandermrix_110630.pdf> [accessed 19/12/2016].
8. [8] Medical Products Agency Sweden. A registry based comparative cohort study in four Swedish counties of the risk for narcolepsy after vaccination with Pandemrix – A first and preliminary report, by the Medical Products Agency. Available from: < http://www.lakemedelsverket.se/upload/nyheter/2011/PandemrixRegReport110328.pdf> (accessed 19/12/2016).
9. [9] Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ, 339, 2009, b2535.
10. [10] Griffin, M.R., Monto, A.S., Belongia, E.A., Treanor, J.J., Chen, Q., Chen, J., et al. Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 U.S. communities. PLoS ONE, 6, 2011 e23085-e.
11. [11] Hadler, J.L., Baker, T.N., Papadouka, V., France, A.M., Zimmerman, C., Livingston, K.A., et al. Effectiveness of 1 dose of 2009 influenza A (H1N1) vaccine at preventing hospitalization with pandemic H1N1 influenza in children aged 7 months-9 years. J Infect Dis 206 (2012), 49–55.
12. [12] Uzicanin, A., Thompson, M., Smith, P., Chaves, S.S., Foster, L., Dube, N., et al. Effectiveness of 1 dose of influenza A (H1N1) 2009 monovalent vaccines in preventing reverse-transcription polymerase chain reaction-confirmed H1N1 infection among school-aged children in Maine. J Infect Dis 206 (2012), 1059–1068.
13. [13] Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from < www.cochrane-handbook.org>.
14. [14] Wells G, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (last accessed 19/12/16).
15. [15] Jackson, M.L., Nelson, J.C., The test-negative design for estimating influenza vaccine effectiveness. Vaccine 31 (2013), 2165–2168.
16. [16] West S, King V, Carey TS, Lohr KN, McKoy N, Sutton SF, et al. Systems to rate the strength of scientific evidence. Evidence report/technology assessment (Summary). 2002:1–11.
17. [17] Systematic Reviews: CRD's guidance for undertaking reviews in health care: Centre for Reviews and Dissemination. University of York; 2009.
18. [18] Andrews, N., Waight, P., Yung, C.F., Miller, E., Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. J Infect Dis 203 (2011), 32–39.
19. [19] Fielding, J.E., Grant, K.A., Garcia, K., Kelly, H.A., Effectiveness of seasonal influenza vaccine against pandemic (H1N1) 2009 virus, Australia, 2010. Emerg Infect Dis 17 (2011), 1181–1187.
20. [20] Hamrin, J., Bennet, R., Eriksson, M., Lind, G., Ortqvist, E., Effectiveness of mono-valent adjuvanted vaccine (Pandemrix) for the prevention of hospitalisation for influenza A (H1N1)v infection in children. Acta Paediatr, 99, 2010, 85.
21. [21] Hellenbrand W, Jorgensen P, Schweiger B, Falkenhorst G, Nachtnebel M, Greutélaers B, et al. Prospective hospital-based case-control study to assess the effectiveness of pandemic influenza A(H1N1)pdm09 vaccination and risk factors for hospitalization in 2009–2010 using matched hospital and test-negative controls. BMC Infect Dis. 12:127.
22. [22] Mahmud, S., Hammond, G., Elliott, L., Hilderman, T., Kurbis, C., Caetano, P., et al. Effectiveness of the pandemic H1N1 influenza vaccines against laboratory-confirmed H1N1 infections: population-based case-control study. Vaccine 29 (2011), 7975–7981.
23. [23] Ortqvist, A., Bennet, R., Rinder, M.R., Lindblad, H., Eriksson, M., Effectiveness of the monovalent AS03-adjuvanted influenza A(H1N1)pdm09 vaccine against hospitalization in children because of influenza. Vaccine 30 (2012), 5699–5702.
24. [24] Puig-Barbera, J., Arnedo-Pena, A., Pardo-Serrano, F., Tirado-Balaguer, M.D., Perez-Vilar, S., Silvestre-Silvestre, E., et al. Effectiveness of seasonal 2008–2009, 2009–2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellon, Spain. A test-negative, hospital-based, case-control study. Vaccine 28 (2010), 7460–7467.
25. [25] Skowronski, D.M., Janjua, N.Z., De Serres, G., Hottes, T.S., Dickinson, J.A., Crowcroft, N., et al. Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. BMJ, 342, 2011, c7297.
26. [26] Song, J.Y., Cheong, H.J., Heo, J.Y., Noh, J.Y., Choi, W.S., Park, D.W., et al. Effectiveness of the pandemic influenza A/H1N1 2009 monovalent vaccine in Korea. Vaccine 29 (2011), 1395–1398.
27. [27] Uphoff H, An der Heiden M, Schweiger B, Campe H, Beier D, Helmeke C, et al. Effectiveness of the AS03-adjuvanted vaccine against pandemic influenza virus A/(H1N1) 2009 – a comparison of two methods; Germany, 2009/10. PLoS One. 2011;6:e19932-e.
28. [28] Van Buynder, P.G., Dhaliwal, J.K., Van Buynder, J.L., Couturier, C., Minville-Leblanc, M., Garceau, R., et al. Protective effect of single-dose adjuvanted pandemic influenza vaccine in children. Influenza Other Respir Viruses 4 (2010), 171–178.
29. [29] Wijnans, L., Dieleman, J., Voordouw, B., Sturkenboom, M., Effectiveness of MF59 Adjuvanted Influenza A(H1N1)pdm09 Vaccine in Risk Groups in the Netherlands. PLoS ONE, 8, 2013.
30. [30] Dominguez, A., Castilla, J., Godoy, P., Delgado-Rodriguez, M., Martin, V., Saez, M., et al. Effectiveness of pandemic and seasonal influenza vaccines in preventing pandemic influenza-associated hospitalization. Vaccine 30 (2012), 5644–5650.
31. [31] Fu, C., Effectiveness of H1N1 vacine against reported Influenza A (H1N1). Human Vaccines 6 (2010), 767–768.
32. [32] Gefenaite, G., Tacken, M., Bos, J., Stirbu-Wagner, I., Korevaar, J.C., Stolk, R.P., et al. Effectiveness of A(H1N1)pdm09 influenza vaccine in adults recommended for annual influenza vaccination. PLoS ONE, 8, 2013, e66125.
33. [33] Gilca, R., Deceuninck, G., De Serres, G., Boulianne, N., Sauvageau, C., Quach, C., et al. Effectiveness of pandemic H1N1 vaccine against influenza-related hospitalization in children. Pediatrics 128 (2011), e1084–e1091.
34. [34] Mahmud, S.M., Bozat-Emre, S., Thompson, L.H., Elliott, L.J., Caeseele, P., Effectiveness of the pandemic H1N1 influenza vaccines in preventing hospitalization for influenza and pneumonia: a population-based case-control study. Pharmacoepidemiol Drug Saf, 22, 2013, 438.
35. [35] Steens, A., Wijnans, E.G., Dieleman, J.P., Sturkenboom, M.C.J.M., van der Sande, M.A.B., van der Hoek, W., et al. A/H1N1 influenza-related hospitalisation; a matched case-control study. BMC Infect Dis, 2011, 2009, 11.
36. [36] Thompson, M.G., Sokolow, L.Z., Almendares, O., Openo, K., Farley, M.M., Meek, J., et al. Effectiveness of nonadjuvanted monovalent influenza A(H1N1)pdm09 vaccines for preventing reverse transcription polymerase chain reaction-confirmed pandemic influenza hospitalizations: case-control study of children and adults at 10 US influenza surveillance network sites. Clin Infect Dis 57 (2013), 1587–1592.
37. [37] Zhang, Y., Seale, H., Yang, P., MacIntyre, C.R., Blackwell, B., Tang, S., et al. Factors associated with the transmission of pandemic (H1N1) 2009 among hospital healthcare workers in Beijing, China. Influenza Other Respir Viruses 7 (2013), 466–471.
38. [38] Emborg, H.D., Krause, T.G., Hviid, A., Simonsen, J., Molbak, K., Effectiveness of vaccine against pandemic influenza A/H1N1 among people with underlying chronic diseases: cohort study, Denmark, 2009–10. BMJ, 344, 2012, d7901.
39. [39] Guzman Herrador, B.R., Aavitsland, P., Feiring, B., Riise Bergsaker, M.A., Borgen, K., Usefulness of health registries when estimating vaccine effectiveness during the influenza A(H1N1)pdm09 pandemic in Norway. BMC Infect Dis, 12, 2012, 63.
40. [40] Lim, J., Choi, B., Kim, J., Kim, J., Kim, C., Park, J., et al. Evaluation and sensitivity analysis of the effectiveness of unadjuvanted A(H1N1)pdm09 vaccine in hospital workers using multi-center cohort study in Korea. Vaccine 31 (2013), 2381–2386.
41. [41] Wu, J., Xu, F., Lu, L., Lu, M., Miao, L., Gao, T., et al. Safety and effectiveness of a 2009 H1N1 vaccine in Beijing. N Engl J Med 363 (2010), 2416–2423.
42. [42] Costa, J.T., Silva, R., Tavares, M., Nienhaus, A., High effectiveness of pandemic influenza A (H1N1) vaccination in healthcare workers from a Portuguese hospital. Int Arch Occup Environ Health 85 (2012), 747–752.
43. [43] He, H.Q., Li, Q., He, B., Gao, W.J., Yao, F.Y., Jiang, X.F., et al. Epidemiological effects of the A (H1N1) influenza vaccine immunization program on students. Zhonghua Liu Xing Bing Xue Za Zhi 32 (2011), 661–663.
44. [44] Lee, V.J., Tan, C.H., Yap, J., Cook, A.R., Ting, P.J., Loh, J.P., et al. Effectiveness of pandemic H1N1-2009 vaccination in reducing laboratory confirmed influenza infections among military recruits in tropical Singapore. PLoS ONE, 6, 2011, e26572.
45. [45] Njuguna, H., Ahmed, J., Oria, P.A., Arunga, G., Williamson, J., Kosgey, A., et al. Uptake and effectiveness of monovalent influenza A (H1N1) pandemic 2009 vaccine among healthcare personnel in Kenya, 2010. Vaccine 31 (2013), 4662–4667.
46. [46] Ortqvist, A., Berggren, I., Insulander, M., de Jong, B., Svenungsson, B., Effectiveness of an adjuvanted monovalent vaccine against the 2009 pandemic strain of influenza A(H1N1)v, in Stockholm County, Sweden. Clin Infect Dis 52 (2011), 1203–1211.
47. [47] Schuurmans, M.M., Tini, G.M., Dalar, L., Fretz, G., Benden, C., Boehler, A., Pandemic 2009 H1N1 influenza virus vaccination in lung transplant recipients: coverage, safety and clinical effectiveness in the Zurich cohort. J Heart Lung Transplant 30 (2011), 685–690.
48. [48] Syrjanen, R.K., Jokinen, J., Ziegler, T., Sundman, J., Lahdenkari, M., Julkunen, I., et al. Effectiveness of pandemic and seasonal influenza vaccines in preventing laboratory-confirmed influenza in Adults: A clinical cohort study during epidemic seasons 2009–2010 and 2010–2011 in Finland. PLoS ONE, 9, 2014.
49. [49] Seyler, T., Bella, A., Puzelli, S., Donatelli, I., Rizzo, C., Screening method working g. Estimating pandemic vaccine effectiveness in two Italian regions using the screening method, 2009–2010. Vaccine 30 (2012), 109–111.
50. [50] Wichmann O, Stocker P, Poggensee G, Altmann D, Walter D, Hellenbrand W, et al. Pandemic influenza A(H1N1) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009–2010. Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2010;15.
51. [51] Broadbent AJ, Subbarao K. Influenza virus vaccines: lessons from the 2009 H1N1 pandemic. Curr Opin Virol. 1:254-62.
52. [52] Partridge, J., Kieny, M.P., Global production of seasonal and pandemic (H1N1) influenza vaccines in 2009–2010 and comparison with previous estimates and global action plan targets. Vaccine 28 (2010), 4709–4712.
53. [53] Klick, B., Durrani, S., Chan, K.H., Ip, D.K., Chou, E.S., Kwok, H.K., et al. Live attenuated seasonal and pandemic influenza vaccine in school-age children: a randomized controlled trial. Vaccine 31 (2013), 1937–1943.
54. [54] Kulkarni, P.S., Agarkhedkar, S., Lalwani, S., Bavdekar, A.R., Jog, S., Raut, S.K., et al. Effectiveness of an Indian-made attenuated influenza A(H1N1)pdm 2009 vaccine: a case control study. Human Vacc Immunother 10 (2014), 566–571.
55. [55] Mallory, R.M., Malkin, E., Ambrose, C.S., Bellamy, T., Shi, L., Yi, T., et al. Safety and immunogenicity following administration of a live, attenuated monovalent 2009 H1N1 influenza vaccine to children and adults in two randomized controlled trials. PLoS ONE, 2010, e13755.
56. [56] Ambrose CS, Bright H, Mallory R. Letter to the editor: potential causes of the decreased effectiveness of the influenza A(H1N1)pdm09 strain in live attenuated influenza vaccines. Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2016;21.
57. [57] Van Kerkhove, M.D., Hirve, S., Koukounari, A., Mounts, A.W., Estimating age-specific cumulative incidence for the 2009 influenza pandemic: a meta-analysis of A(H1N1)pdm09 serological studies from 19 countries. Influenza Other Respir Viruses 7 (2013), 872–886.
58. [58] Vesikari, T., Knuf, M., Wutzler, P., Karvonen, A., Kieninger-Baum, D., Schmitt, H.J., et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 365 (2011), 1406–1416.
59. [59] Biggerstaff, M., Reed, C., Swerdlow, D.L., Gambhir, M., Graitcer, S., Finelli, L., et al. Estimating the potential effects of a vaccine program against an emerging influenza pandemic–United States. Clin Infect Dis 60:Suppl 1 (2015), S20–S29.
60. [60] Borse, R.H., Shrestha, S.S., Fiore, A.E., Atkins, C.Y., Singleton, J.A., Furlow, C., et al. Effects of vaccine program against pandemic influenza A(H1N1) virus, United States, 2009–2010. Emerg Infect Dis 19 (2013), 439–448.
61. [61] World Health Organization. Pandemic influenza preparedness framework for the sharing of influenza viruses and access to vaccines and other benefits; 2011.
62. [62] Jennings, L.C., Monto, A.S., Chan, P.K., Szucs, T.D., Nicholson, K.G., Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. Lancet Infect Dis 8 (2008), 650–658.
63. [63] Nicholson, K.G., Abrams, K.R., Batham, S., Clark, T.W., Hoschler, K., Lim, W.S., et al. Immunogenicity and safety of a two-dose schedule of whole-virion and AS03A-adjuvanted 2009 influenza A (H1N1) vaccines: a randomised, multicentre, age-stratified, head-to-head trial. Lancet Infect Dis 11 (2011), 91–101.
64. [64] Lee, S., Golinski, M., Chowell, G., Modeling optimal age-specific vaccination strategies against pandemic influenza. Bull Math Biol 74 (2012), 958–980.
65. [65] Shim, E., Prioritization of delayed vaccination for pandemic influenza. Math Biosci Eng 8 (2011), 95–112.
66. [66] Nakanishi, M., Yoshida, Y., Takeda, N., Hirana, H., Horita, T., Shimizu, K., et al. Community-acquired pneumonia distinguished from influenza infection based on clinical signs and symptoms during a novel (swine) influenza A/H1N1 pandemic. Primary Care Respiratory J, 02, 2011.
67. [67] Pebody RG, Green HK, Andrews N, Boddington NL, Zhao H, Yonova I, et al. Uptake and impact of vaccinating school age children against influenza during a season with circulation of drifted influenza A and B strains, England, 2014/15. Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2015;20.
68. [68] Wood, J., McCaw, J., Becker, N., Nolan, T., MacIntyre, C.R., Optimal dosing and dynamic distribution of vaccines in an influenza pandemic. Am J Epidemiol 169 (2009), 1517–1524.
69. [69] Sturkenboom, M.C., The narcolepsy-pandemic influenza story: can the truth ever be unraveled?. Vaccine 33:Suppl 2 (2015), B6–B13.